Vienna (Austria), July 4, 2007 – H.M. Pharma Consultancy has identified, and is already addressing, an emerging market opportunity: assisting companies in drug regulatory and reimbursement applications in Central and Eastern European markets.

“Small and mid-sized overseas companies who want to launch a new drug in the Central and Eastern European countries usually lack a direct local representation there,” said Dr. Hermann Mucke, H.M. Pharma Consultancy’s founder and owner. “Even if the company has secured EMEA marketing authorization via the centralized regulatory process, there are still significant hurdles to overcome before the product reaches the pharmacy shelves and is appropriately reimbursed upon prescription. These hurdles are different in each country, and can cause launch delays if not addressed in a timely and knowledgeable fashion. We have identified this situation as a significant business opportunity, and during the past months we have already secured business in this emerging field. A few days ago we filed the first reimbursement application for an EMEA-approved new drug for one of our clients in Austria, and are negotiating related projects for Hungary, Slovenia, and Bulgaria – countries where H.M. Pharma Consultancy is well connected. We are excited about being able to offer this new service, and are looking forward to assist more companies – especially from the U.S. and Asia – as they make their first moves into the central and south-eastern EU member states.”